ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Oppenheimer

Oppenheimer initiated coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report published on Friday, MarketBeat Ratings reports. The firm issued an outperform rating and a $15.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on PRQR. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $6.00 to $14.00 in a report on Tuesday, October 29th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR opened at $2.42 on Friday. The company has a market cap of $197.67 million, a P/E ratio of -7.56 and a beta of 0.30. The firm’s fifty day moving average is $3.23 and its two-hundred day moving average is $2.52. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

A number of large investors have recently made changes to their positions in PRQR. Privium Fund Management B.V. boosted its position in ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares during the period. OneDigital Investment Advisors LLC boosted its position in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the period. 32.65% of the stock is owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).